Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV.
Sellem B, Abdi B, Lê M, Tubiana R, Valantin MA, Seang S, Schneider L, Fayçal A, Peytavin G, Soulié C, Marcelin AG, Katlama C, Pourcher V, Palich R. Sellem B, et al. Among authors: peytavin g. J Pers Med. 2023 Mar 27;13(4):583. doi: 10.3390/jpm13040583. J Pers Med. 2023. PMID: 37108969 Free PMC article.
Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.
Mouroux M, Yvon-Groussin A, Peytavin G, Delaugerre C, Legrand M, Bossi P, Do B, Trylesinski A, Diquet B, Dohin E, Delfraissy JF, Katlama C, Calvez V. Mouroux M, et al. Among authors: peytavin g. J Clin Microbiol. 2000 Jul;38(7):2726-30. doi: 10.1128/JCM.38.7.2726-2730.2000. J Clin Microbiol. 2000. PMID: 10878071 Free PMC article. Clinical Trial.
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Delaugerre C, Marcelin AG, Thibault V, Peytavin G, Bombled T, Bochet MV, Katlama C, Benhamou Y, Calvez V. Delaugerre C, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2002 May;46(5):1586-8. doi: 10.1128/AAC.46.5.1586-1588.2002. Antimicrob Agents Chemother. 2002. PMID: 11959607 Free PMC article.
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V; Genophar Study Group. Marcelin AG, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2003 Feb;47(2):594-600. doi: 10.1128/AAC.47.2.594-600.2003. Antimicrob Agents Chemother. 2003. PMID: 12543665 Free PMC article. Clinical Trial.
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
Wirden M, Simon A, Schneider L, Tubiana R, Paris L, Marcelin AG, Delaugerre C, Legrand M, Herson S, Peytavin G, Katlama C, Calvez V. Wirden M, et al. Among authors: peytavin g. J Clin Microbiol. 2003 Jun;41(6):2713-5. doi: 10.1128/JCM.41.6.2713-2715.2003. J Clin Microbiol. 2003. PMID: 12791913 Free PMC article.
486 results